Sight Sciences (SGHT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Sight Sciences, Inc. reported $19.91 million in revenue for Q3 2025, a year-over-year decline of 1.3% [1] - The company achieved an EPS of -$0.16, an improvement from -$0.22 a year ago, with a surprise of +38.46% compared to the consensus estimate of -$0.26 [1] - Revenue exceeded the Zacks Consensus Estimate of $17.16 million by +15.98% [1] Revenue Breakdown - Dry Eye revenue was $0.19 million, significantly below the average estimate of $0.25 million, representing a year-over-year decline of -87.7% [4] - Surgical Glaucoma revenue was $19.72 million, surpassing the estimated $16.91 million, reflecting a year-over-year increase of +5.8% [4] Profit Metrics - Gross Profit for Dry Eye was $0.07 million, below the estimated $0.13 million [4] - Gross Profit for Surgical Glaucoma was $17.13 million, exceeding the average estimate of $13.77 million [4] Stock Performance - Shares of Sight Sciences have returned +45% over the past month, outperforming the Zacks S&P 500 composite's +1.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3]